Content about Precancerous condition

December 12, 2012
Galderma Pharma to acquire Spirig Pharma

Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

LAUSANNE, Switzerland — Swiss skin drug maker Galderma Pharma will acquire another Swiss drug maker also focused on treatments for skin conditions, Galderma said.

Based in Egerkingen, Switzerland, Spirig makes treatments for such conditions as solar damage and skin barrier function impairment, as well as treatments for such precancerous conditions as actinic keratosis. Financial terms of the deal were not disclosed, though it was noted that Spirig had sales of about $106 million in 2011. The global corporate headquarters of Galderma will remain in Lausanne, Switzerland.

January 25, 2012
FDA approves actinic keratosis treatment

The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

PARSIPPANY, N.J. — The Food and Drug Administration has approved a topical treatment made by Leo Pharma for a skin condition that can lead to cancer, the drug maker said Wednesday.

Leo announced the FDA approval of Picato (ingenol mebutate) gel in the 0.015%/0.05% strength for actinic keratosis, also known as AK, which is a precancerous condition resulting from cumulative sun exposure that has the potential to lead to squamous cell carcinoma.

July 19, 2011
Graceway receives regulatory approval for Zyclara

The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

BRISTOL, Tenn. — The Food and Drug Administration has approved a drug made by Graceway Pharmaceuticals for actinic keratoses, Graceway said.

The agency approved Zyclara (imiquimod) cream in the 2.5% strength for AK, a precancerous lesion that affects about 10 million Americans and can develop into skin cancer later on.